https://kuraoncology.com/wp-content/uploads/pharma_voice_gears.jpeg
450
800
eallison
/wp-content/uploads/kura-logo.svg
eallison2023-05-18 08:00:542023-05-23 13:57:17What pharma can teach biotech about the life cycle management of a drug
https://kuraoncology.com/wp-content/uploads/BioCentury_0201_DB_DoseOptim.png
646
1246
David Anderson
/wp-content/uploads/kura-logo.svg
David Anderson2023-02-01 08:00:002023-02-07 14:03:52Navigating dose optimization requirements as a small biotech
https://kuraoncology.com/wp-content/uploads/LiquidBiopsies_GettyImages-1325872227-1068x712-1.jpg
712
1068
David Anderson
/wp-content/uploads/kura-logo.svg
David Anderson2022-09-06 14:25:062023-01-05 12:40:46Liquid Biopsies Guide the Development of Cancer Drugs
https://kuraoncology.com/wp-content/uploads/troy_wilson_lab.png
478
850
David Anderson
/wp-content/uploads/kura-logo.svg
David Anderson2021-06-28 12:00:192022-12-01 16:51:22Fierce Biotech: FDA’s renewed focus on oncology dosing spooks investors, but companies say they’re ready
https://kuraoncology.com/wp-content/uploads/AdobeStock_207889815-scaled.jpg
1709
2560
David Anderson
/wp-content/uploads/kura-logo.svg
David Anderson2021-04-21 12:00:292022-11-16 13:32:04ESMO: Tipifarnib demonstrates encouraging efficacy in patients with recurrent and/or metastatic hnscc with hras mutations
https://kuraoncology.com/wp-content/uploads/Kura_Dawn-of-Medicine-Article-img-scaled.jpeg
1709
2560
David Anderson
/wp-content/uploads/kura-logo.svg
David Anderson2021-04-20 06:00:022022-11-16 13:25:55Journal of Clinical Oncology: Is This the Dawn of Precision Oncology in Head and Neck Cancer?
Scroll to top